These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
116 related items for PubMed ID: 20880381
1. Platelet transfusion refractoriness attributable to HLA antibodies produced by donor-derived cells after allogeneic bone marrow transplantation from one HLA-antigen-mismatched mother. Hatakeyama N, Hori T, Yamamoto M, Inazawa N, Iesato K, Miyazaki T, Ikeda H, Tsutsumi H, Suzuki N. Pediatr Transplant; 2011 Dec; 15(8):E177-82. PubMed ID: 20880381 [Abstract] [Full Text] [Related]
4. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children]. Pereira J, Bronfman L, Bertín P, Marzouka E, Hidalgo P, Amaya S, Mezzano D. Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051 [Abstract] [Full Text] [Related]
5. Treatment of acute leukemia with unmanipulated HLA-mismatched/haploidentical blood and bone marrow transplantation. Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W, Chen YH, Zhang XH, Lu DP. Biol Blood Marrow Transplant; 2009 Feb; 15(2):257-65. PubMed ID: 19167686 [Abstract] [Full Text] [Related]
6. CD6+ T cell depleted allogeneic bone marrow transplantation from genotypically HLA nonidentical related donors. Soiffer RJ, Mauch P, Fairclough D, Alyea E, Anderson K, Fisher D, Freedman A, Bartlett-Pandite L, Robertson M, Schlossman R, Gollob J, Marcus K, Murray C, Kuhlman C, Freeman A, Nadler L, Ritz J. Biol Blood Marrow Transplant; 1997 Apr; 3(1):11-7. PubMed ID: 9209736 [Abstract] [Full Text] [Related]
7. Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation. Toor AA, Choo SY, Little JA. Bone Marrow Transplant; 2000 Aug; 26(3):315-20. PubMed ID: 10967572 [Abstract] [Full Text] [Related]
8. Pretransplant platelet transfusion refractoriness is not associated with platelet nonengraftment in T-replete hematopoietic progenitor cell transplantation for hematologic malignancies. Scott A, Baidya S, Butler J, Morris K, Thornton A, Kennedy GA. Transfusion; 2016 Jan; 56(1):164-9. PubMed ID: 26264674 [Abstract] [Full Text] [Related]
9. Acute graft-versus-host disease after bone marrow transplantation with a single HLA-DPB1*1001 mismatch: involvement of different TCRBV subsets. Gaschet J, Gallot G, Ibisch C, Lim A, Even J, Vivien R, Hallet MM, Milpied N, Vié H. Bone Marrow Transplant; 1998 Aug; 22(4):385-92. PubMed ID: 9722075 [Abstract] [Full Text] [Related]
10. [Unrelated donor allogenetic marrow transplantation in treatment of acute and chronic leukemia]. Huang H, Lin M, Meng H. Zhonghua Yi Xue Za Zhi; 2001 Mar 10; 81(5):263-7. PubMed ID: 11798883 [Abstract] [Full Text] [Related]
11. [Successful donor lymphocyte infusion for Epstein-Barr virus-associated lymphoproliferative disorder after allogeneic bone marrow transplantation from an HLA 1-locus-mismatched sibling donor in a patient with acute lymphocytic leukemia]. Yago K, Itoh M, Shimada H. Rinsho Ketsueki; 2001 Nov 10; 42(11):1105-10. PubMed ID: 11808079 [Abstract] [Full Text] [Related]
12. Factors leading to the appearance, after BMT, of cytotoxic antibodies against T, B and activated T lymphocytes: critical appraisal. Martinetti M, Conte R, Nespoli L, Capelli E, Salvaneschi L, Porta F, Prete L, Cuccia M. Haematologica; 1990 Nov 10; 75(5):429-35. PubMed ID: 2097261 [Abstract] [Full Text] [Related]
13. Platelet transfusion refractoriness due to graft-derived anti-HPA-2b production after allogeneic bone-marrow transplantation. Taaning E, Jacobsen N. Transplant Proc; 1994 Jun 10; 26(3):1826. PubMed ID: 8030157 [No Abstract] [Full Text] [Related]
14. [Basedow disease occurring after allogeneic bone marrow transplantation for acute lymphoblastic leukemia]. Sasaki Y, Ito K. Rinsho Ketsueki; 2002 Sep 10; 43(9):833-5. PubMed ID: 12412287 [Abstract] [Full Text] [Related]
15. Recipient-derived HPA-1a antibodies: a cause of prolonged thrombocytopenia after unrelated donor stem cell transplantation. Lucas G, Culliford S, Green F, Sidra G, Calvert A, Green A, Harrison P, Harvey J, Allen D, Smillie D, Masurekar A, Marks D, Russell N, Massey E. Transfusion; 2010 Feb 10; 50(2):334-9. PubMed ID: 19874563 [Abstract] [Full Text] [Related]
16. Minor histocompatibility antigen-specific, leukemia-reactive cytotoxic T cell clones can be generated in vitro without in vivo priming using chronic myeloid leukemia cells as stimulators in the presence of alpha-interferon. Faber LM, van Luxemburg-Heijs SA, Rijnbeek M, Willemze R, Falkenburg JH. Biol Blood Marrow Transplant; 1996 Feb 10; 2(1):31-6. PubMed ID: 9078352 [Abstract] [Full Text] [Related]
17. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R. Exp Hematol; 1995 Dec 10; 23(14):1553-62. PubMed ID: 8542946 [Abstract] [Full Text] [Related]
18. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. Keever-Taylor CA, Passweg J, Kawanishi Y, Casper J, Flomenberg N, Baxter-Lowe LA. Bone Marrow Transplant; 1997 May 10; 19(10):1001-9. PubMed ID: 9169644 [Abstract] [Full Text] [Related]
19. Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens. Schultz KR, Ratanatharathorn V, Abella E, Eisenbrey AB, Karanes C, Lum LG, de Planque MM, Uberti JP, Ravindranath Y, Sensenbrenner LL. Bone Marrow Transplant; 1994 Jun 10; 13(6):817-22. PubMed ID: 7920320 [Abstract] [Full Text] [Related]